Loading…
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $13M | $-80M | $-69M | $-77M | -33.5% | - | - |
| 2024 | $0M | $0M | $0M | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2024 | 2025 |
|---|---|---|
| Total Revenue | 0 | 13 |
| Operating Expense | 0 | 94.07 |
| Operating Income | 0 | -81.07 |
| EBITDA | 0 | -79.68 |
| EBIT | 0 | -81.07 |
| Pretax Income | 0 | -68.87 |
| Net Income | 0 | -68.87 |
| Net Income Common Stockholders | 0 | -68.87 |
| Total Expenses | 0 | 94.07 |
| Interest Income | 0 | 3.32 |
| Research And Development | 0 | 74.04 |
| Selling General And Administration | 0 | 20.03 |
| Normalized EBITDA | 0 | -88.61 |
| Normalized Income | 0 | -77.80 |
| Basic EPS | -4.27 | 0 |
| Diluted EPS | -4.27 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 |
| Total Unusual Items | 0 | 8.93 |
| Total Unusual Items Excluding Goodwill | 0 | 8.93 |
| Net Income From Continuing Operation Net Minority Interest | 0 | -68.87 |
| Reconciled Depreciation | 0 | 1.39 |
| Net Interest Income | 0 | 3.32 |
| Net Income From Continuing And Discontinued Operation | 0 | -68.87 |
| Total Operating Income As Reported | 0 | -81.07 |
| Diluted Average Shares | 16 | 0 |
| Basic Average Shares | 16 | 0 |
| Diluted NI Availto Com Stockholders | 0 | -68.87 |
| Otherunder Preferred Stock Dividend | 0 | 0 |
| Net Income Including Noncontrolling Interests | 0 | -68.87 |
| Net Income Continuous Operations | 0 | -68.87 |
| Other Income Expense | 0 | 8.88 |
| Other Non Operating Income Expenses | 0 | -0.05 |
| Gain On Sale Of Security | 0 | 8.93 |
| Net Non Operating Interest Income Expense | 0 | 3.32 |
| Interest Income Non Operating | 0 | 3.32 |
| General And Administrative Expense | 0 | 20.03 |
| Other Gand A | 0 | 7.48 |
| Salaries And Wages | 0 | 12.54 |
| Operating Revenue | 0 | 13 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| EVMNthis co. | EVMN | $859M | - | 3.66 | -33.5% | -8.93 |
| LB Pharmaceuticals Inc | LBRX | $877M | - | 2.57 | -8.4% | -20.06 |
| Bright Minds Biosciences Inc. | DRUG | $872M | - | 10.63 | -14.9% | - |
| Talkspace, Inc. | TALK | $869M | 129.75 | 7.39 | 6.7% | 128.51 |
| SELLAS Life Sciences Group, Inc. | SLS | $862M | - | 10.09 |
| -37.9% |
| - |
| Janux Therapeutics, Inc. | JANX | $860M | - | 0.89 | -11.9% | 0.55 |
| Theravance Biopharma, Inc. | TBPH | $859M | 8.09 | 2.87 | 35.7% | -296.42 |
| MannKind Corporation | MNKD | $849M | 137.50 | -16.57 | -11.5% | 19.49 |
| Omada Health, Inc. | OMDA | $841M | - | 3.60 | -5.6% | -94.35 |
| Peer Median | - | 129.75 | 3.23 | -9.9% | -9.76 | |